AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31626696 — intervention group
Group type: COMPARATOR
Intervention: Phentermine HCl 60 mg
Number of subjects: 38
Study 31626696 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitolisant 35.6 mg
Number of subjects: 38
Study 31626696 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitolisant 213.6 mg
Number of subjects: 38
Study 31626696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 31522078 — intervention group
Group type: EXPERIMENTAL
Intervention: Below-knee compression garment (BK)
Number of subjects: 16
Study 31522078 — intervention group
Group type: EXPERIMENTAL
Intervention: Above-knee compression garment (AK)
Number of subjects: 16
Study 31522078 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-knee compression garment (WK)
Number of subjects: 16
Study 31522078 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 16
Study 28277845 — intervention group
Group type: EXPERIMENTAL
Intervention: New mometasone furoate cream
Number of subjects: 162
Study 28277845 — intervention group
Group type: COMPARATOR
Intervention: Positive control (marketed Elocon cream)
Number of subjects: 162
Study 25586724 — intervention group
Group type: EXPERIMENTAL
Intervention: sugammadex 1.0 mg kg(‐1)
Number of subjects: 300
Study 25586724 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 300
Study 25222806 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBSSL treatment
Number of subjects: 63
Study 25222806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 22751847 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod, 0.5 mg
Number of subjects: 1272
Study 22751847 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod, 1.25 mg
Number of subjects: 1272
Study 22751847 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod (both doses)
Number of subjects: 1272
Study 22751847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1272
Study 21375019 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment for 30 min, once daily for 4 weeks.
Number of subjects: 80
Study 21375019 — intervention group
Group type: COMPARATOR
Intervention: Mecobalamine (500 microg) intramuscular injection, once daily for 4 weeks.
Number of subjects: 80
Study 21375019 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 80
Study 21375019 — intervention group
Group type: COMPARATOR
Intervention: Mecobalamine treatment
Number of subjects: 80
Study 17699944 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dexamethasone 200 mg once daily for three days
Number of subjects: 21
Study 17699944 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone 250 mg/six-hourly for three days followed by oral prednisolone for 11 days
Number of subjects: 21
Study 16045572 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraflex expandable stent
Number of subjects: 65
Study 16045572 — intervention group
Group type: COMPARATOR
Intervention: High-dose-rate endoluminal brachytherapy (7 Gy x 3 given in 2-4 weeks)
Number of subjects: 65
Study 12163429 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary brachytherapy
Number of subjects: 252
Study 12163429 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (placebo)
Number of subjects: 252
Study 10429771 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg dolasetron orally 45‐60 minutes before anaesthesia
Number of subjects: 80
Study 10429771 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg i.v. DHB + placebo p.o. (positive control group)
Number of subjects: 80
Study 10429771 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg dolasetron orally 45‐60 minutes before anaesthesia and 2.5 mg i.v. DHB during anaesthesia
Number of subjects: 80
Study 10429771 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet administered 45‐60 minutes before anaesthesia (negative control group)
Number of subjects: 80
Study 8680536 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 400 mg twice daily for 6 weeks
Number of subjects: 50
Study 8680536 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-therapy (300 mg amoxicillin granules and 250 mg metronidazole thrice daily for 2 weeks + cimetidine)
Number of subjects: 50
Study 1299500 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplementation (PRO)
Number of subjects: 11
Study 1299500 — intervention group
Group type: COMPARATOR
Intervention: Wingate test (WIN)
Number of subjects: 11
Study 6432001 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg)
Number of subjects: 0
Study 6432001 — intervention group
Group type: EXPERIMENTAL
Intervention: Niludipine (20 mg)
Number of subjects: 0
Study 6432001 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (chronic administration)
Number of subjects: 0
Study 6432001 — intervention group
Group type: EXPERIMENTAL
Intervention: Niludipine (chronic administration)
Number of subjects: 0
Study 30885134 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (2 mg/kg bolus followed by 1.5 mg/kg/h infusion)
Number of subjects: 120
Study 30885134 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine (0.5 μg/kg bolus followed by 0.4 μg/kg/h infusion)
Number of subjects: 120
Study 30885134 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 120
Study 28864244 — intervention group
Group type: EXPERIMENTAL
Intervention: High quadriceps activation battery (≥4/6)
Number of subjects: 162
Study 28864244 — intervention group
Group type: COMPARATOR
Intervention: Low quadriceps activation battery (≤3/6)
Number of subjects: 162
Study 27651882 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF) plus amniotic membrane (AM)
Number of subjects: 11
Study 27651882 — intervention group
Group type: COMPARATOR
Intervention: Coronally advanced flap (CAF) with connective tissue graft (CTG)
Number of subjects: 11
Study 24477319 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of parathyroid hormone (PTH) for 6 weeks
Number of subjects: 0
Study 24477319 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (standard care)
Number of subjects: 0
Study 22449836 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnically-targeted statement in direct mail letters
Number of subjects: 30000
Study 22449836 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized letters
Number of subjects: 30000
Study 22449836 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct mail letters for minority women
Number of subjects: 30000
Study 22449836 — intervention group
Group type: COMPARATOR
Intervention: Direct mail letters
Number of subjects: 30000
Study 19123156 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral supplementation with EPA (720 mg/day) and DHA (480 mg/day) for 6 months
Number of subjects: 38
Study 19123156 — intervention group
Group type: COMPARATOR
Intervention: Control group (16 patients)
Number of subjects: 38
Study 17242426 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (1.2 mg/kg daily for 3 weeks)
Number of subjects: 18
Study 17242426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 15970715 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose heparin (600 U/kg)
Number of subjects: 40
Study 15970715 — intervention group
Group type: COMPARATOR
Intervention: Low dose heparin (300 U/kg)
Number of subjects: 40
Study 12021557 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-writing group
Number of subjects: 26
Study 12021557 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 26
Study 9728773 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic pure-tone audiometry in a typical practice setting
Number of subjects: 119
Study 9728773 — intervention group
Group type: COMPARATOR
Intervention: Standardized audiological setting
Number of subjects: 119
Study 7895538 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure fat meal (25 g triglycerides)
Number of subjects: 6
Study 7895538 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meal (8 g fat, 10 g protein, 32 g dextrose)
Number of subjects: 6
Study 7895538 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-free meal (25 g albumin, 32 g dextrose)
Number of subjects: 6
Study 2403903 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodinated glycerol (Organidin), 60 mg qid
Number of subjects: 361
Study 2403903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 361
Study 79028 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiography (E.R.C.)
Number of subjects: 0
Study 79028 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cholangiography (I.V.C.)
Number of subjects: 0
Study 31795799 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological care
Number of subjects: 42
Study 31795799 — intervention group
Group type: COMPARATOR
Intervention: Control (no psychological care)
Number of subjects: 42
Study 31446464 — intervention group
Group type: EXPERIMENTAL
Intervention: New two-thumb technique (nTTT)
Number of subjects: 10
Study 31446464 — intervention group
Group type: EXPERIMENTAL
Intervention: Knocking-fingers technique (KF)
Number of subjects: 10
Study 31446464 — intervention group
Group type: COMPARATOR
Intervention: Two-thumb-encircling hand techniques (TTHT)
Number of subjects: 10
Study 27515478 — intervention group
Group type: EXPERIMENTAL
Intervention: MAL-PDT (methyl aminolevulinate photodynamic therapy)
Number of subjects: 40
Study 27515478 — intervention group
Group type: COMPARATOR
Intervention: pPDT (placebo photodynamic therapy)
Number of subjects: 40
Study 26077585 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration using various aspiration catheters (Eliminate, Export, Pronto)
Number of subjects: 0
Study 26077585 — intervention group
Group type: COMPARATOR
Intervention: Thrombus aspiration
Number of subjects: 0
Study 26077585 — intervention group
Group type: COMPARATOR
Intervention: Drug-eluting stents with thrombus aspiration
Number of subjects: 0
Study 26077585 — intervention group
Group type: COMPARATOR
Intervention: Postdilation with thrombus aspiration
Number of subjects: 0
Study 26077585 — intervention group
Group type: COMPARATOR
Intervention: Thrombus aspiration and percutaneous coronary intervention
Number of subjects: 0
Study 23582934 — intervention group
Group type: EXPERIMENTAL
Intervention: levothyroxine+iron salt
Number of subjects: 60
Study 23582934 — intervention group
Group type: EXPERIMENTAL
Intervention: levothyroxine+placebo
Number of subjects: 60
Study 23582934 — intervention group
Group type: COMPARATOR
Intervention: iron salt+placebo
Number of subjects: 60
Study 21671745 — intervention group
Group type: EXPERIMENTAL
Intervention: Points of unpredictability in the movie where prediction was more difficult.
Number of subjects: 0
Study 21671745 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased activity in midbrain and striatal regions associated with dopamine release.
Number of subjects: 0
Study 19637397 — intervention group
Group type: COMPARATOR
Intervention: Donepezil (5 mg)
Number of subjects: 0
Study 16563810 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment with additional brace treatment
Number of subjects: 117
Study 16563810 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment alone
Number of subjects: 117
Study 15283826 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (50, 100, 150 microg x kg(‐1), maximum dose 8 mg) with ondansetron (50 microg x kg(‐1))
Number of subjects: 102
Study 15283826 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 102
Study 11739137 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 1000 microg/d (stepdown approach)
Number of subjects: 0
Study 11739137 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate 200 microg/d (constant dose approach)
Number of subjects: 0
Study 11739137 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (both approaches)
Number of subjects: 0
Study 9234035 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 195
Study 9234035 — intervention group
Group type: COMPARATOR
Intervention: No alcohol consumption (control)
Number of subjects: 195
Study 8424427 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoblastoid alpha-interferon (L-IFN)
Number of subjects: 40
Study 8424427 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 40
Study 3687269 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenteric anaesthesia according to Finsterer
Number of subjects: 50
Study 3687269 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia without mesenteric anaesthesia
Number of subjects: 50
Study 28735368 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (75 mg)
Number of subjects: 20
Study 28735368 — intervention group
Group type: COMPARATOR
Intervention: Ketanserin (40 mg) as pre-treatment
Number of subjects: 20
Study 27113325 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching (SS) intervention for the hamstrings of their dominant leg for 4 weeks
Number of subjects: 30
Study 27113325 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 25436319 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Therapy (HAIC plus systemic chemotherapy)
Number of subjects: 106
Study 25436319 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (systemic chemotherapy alone)
Number of subjects: 106
Study 21086017 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium bromide therapy for 4 years
Number of subjects: 5993
Study 21086017 — intervention group
Group type: COMPARATOR
Intervention: Routine COPD care (RC)
Number of subjects: 5993
Study 20380708 — intervention group
Group type: EXPERIMENTAL
Intervention: Activ-L Artificial Disc
Number of subjects: 414
Study 20380708 — intervention group
Group type: COMPARATOR
Intervention: Charité Artificial Disc [DePuy Spine] or ProDisc-L Total Disc Replacement [Synthes Spine]
Number of subjects: 414
Study 18166745 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA-Proseal (PLMA)
Number of subjects: 51
Study 18166745 — intervention group
Group type: COMPARATOR
Intervention: LMA-Classic (CLMA)
Number of subjects: 51
Study 16105333 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 75 mg intramuscularly (i.m.) 30 min before the procedure
Number of subjects: 0
Study 16105333 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg i.m. 30 min before the procedure, together with local infiltration of the cervix with lignocaine 1% (10 mL)
Number of subjects: 0
Study 16105333 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg i.m. 30 min before the procedure together with local infiltration of the cervix with lignocaine 1% (10 mL) and paracervical block with lignocaine 1% (5 mL)
Number of subjects: 0
Study 11788216 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray (1-mg nicotine)
Number of subjects: 16
Study 11788216 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoke (1-mg nicotine, 12 mg tar)
Number of subjects: 16
Study 11788216 — intervention group
Group type: COMPARATOR
Intervention: Control (Nitroglycerin-induced dilation)
Number of subjects: 16
Study 10037314 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabexate mesilate (GM) administered continuously at 1.5 mg/kg per hour from the beginning of anesthesia until the third postoperative day (preop GM group)
Number of subjects: 11
Study 10037314 — intervention group
Group type: COMPARATOR
Intervention: Gabexate mesilate (GM) administered continuously at 1.5 mg/kg per hour from the end of surgery and for the same postoperative period (postop GM group)
Number of subjects: 11
Study 10037314 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabexate mesilate (GM)
Number of subjects: 11
Study 10037314 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabexate mesilate (GM) administered in the preop GM group
Number of subjects: 11
Study 7565999 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial monitoring
Number of subjects: 66
Study 7565999 — intervention group
Group type: COMPARATOR
Intervention: Preprandial monitoring
Number of subjects: 66
Study 2309827 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ethinyl estradiol and norethindrone acetate (various doses)
Number of subjects: 77
Study 2309827 — intervention group
Group type: COMPARATOR
Intervention: Conjugated estrogens 0.625 mg and medroxyprogesterone acetate 10 mg
Number of subjects: 77
Study 2309827 — intervention group
Group type: COMPARATOR
Intervention: Calcium only
Number of subjects: 77
Study 48835 — intervention group
Group type: COMPARATOR
Intervention: Insulin alone
Number of subjects: 14
Study 48835 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol and insulin
Number of subjects: 14
Study 31139687 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive exercise regimen (IER, five sessions/week)
Number of subjects: 65
Study 31139687 — intervention group
Group type: COMPARATOR
Intervention: Usual exercise regimen (UER, two sessions/week)
Number of subjects: 65
Study 29118975 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adhering flowable resin composite (Vertise™Flow)
Number of subjects: 16
Study 29118975 — intervention group
Group type: COMPARATOR
Intervention: Total-etch resin composite (Te-Econom Plus)
Number of subjects: 16
Study 25213161 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg once daily for weeks 1-3 of each 4-week cycle
Number of subjects: 760
Study 25213161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 760
Study 25213161 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 760
Study 24187864 — intervention group
Group type: EXPERIMENTAL
Intervention: BHY group (BHY instant granules, 6 g, twice per day)
Number of subjects: 60
Study 24187864 — intervention group
Group type: COMPARATOR
Intervention: Control group (piracetam, 0.8 g, 3 times per day)
Number of subjects: 60
Study 22048559 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based cognitive behavioral stress management intervention (Coping With Cancer Workbook)
Number of subjects: 123
Study 19210020 — intervention group
Group type: COMPARATOR
Intervention: Selection of reciprocal friends
Number of subjects: 1886
Study 19210020 — intervention group
Group type: COMPARATOR
Intervention: Selection of nonreciprocal friends
Number of subjects: 1886
Study 19210020 — intervention group
Group type: COMPARATOR
Intervention: Influence from nonreciprocal friends
Number of subjects: 1886
Study 19210020 — intervention group
Group type: COMPARATOR
Intervention: Influence from parents
Number of subjects: 1886
Study 19210020 — intervention group
Group type: COMPARATOR
Intervention: Influence from siblings
Number of subjects: 1886
Study 16420200 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin up to 20 mg/d for 15 weeks
Number of subjects: 80
Study 16420200 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 15 weeks
Number of subjects: 80
Study 15612606 — intervention group
Group type: EXPERIMENTAL
Intervention: Large win on the 1st play
Number of subjects: 4
Study 15612606 — intervention group
Group type: EXPERIMENTAL
Intervention: Large win on the 5th play
Number of subjects: 4
Study 15612606 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 small wins on the 2nd and 5th plays
Number of subjects: 4
Study 15612606 — intervention group
Group type: COMPARATOR
Intervention: No wins
Number of subjects: 4
Study 11242737 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum regimen
Number of subjects: 35
Study 11242737 — intervention group
Group type: COMPARATOR
Intervention: Teachers' acceptance of the chewing program
Number of subjects: 35
Study 10678020 — intervention group
Group type: EXPERIMENTAL
Intervention: SPLPV (splenectomy plus ligation of pericardial vein)
Number of subjects: 26
Study 10678020 — intervention group
Group type: COMPARATOR
Intervention: Shunt
Number of subjects: 26
Study 7698862 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable osteosynthetic implants of ultra high strength poly-L-lactide (PLLA)
Number of subjects: 143
Study 3556192 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal nifedipine 20 mg
Number of subjects: 27
Study 3556192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 29239148 — intervention group
Group type: EXPERIMENTAL
Intervention: AutoTIVA
Number of subjects: 132
Study 29239148 — intervention group
Group type: COMPARATOR
Intervention: DES
Number of subjects: 132
Study 29239148 — intervention group
Group type: COMPARATOR
Intervention: SEVO
Number of subjects: 132
Study 29239148 — intervention group
Group type: COMPARATOR
Intervention: ManualTIVA
Number of subjects: 132
Study 27110823 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic unimolecular pentavalent carbohydrate vaccine (Globo‐H, GM2, sTn, TF, and Tn) conjugated to keyhole limpet haemocyanin (KLH) mixed with immunological adjuvant QS‐21 at doses of 25, 50, and 100 mcg.
Number of subjects: 24
Study 27110823 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 24
Study 26211161 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition
Number of subjects: 0
Study 26211161 — intervention group
Group type: COMPARATOR
Intervention: Normal liquid diet
Number of subjects: 0
Study 23687780 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led case management program (monthly telephone calls, motivational interviewing for lifestyle change, home BP monitoring, dosettes for medication administration)
Number of subjects: 56
Study 23687780 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 56
Study 20212061 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium hydrochloride
Number of subjects: 35
Study 20212061 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal electrical stimulation
Number of subjects: 35
Study 20212061 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 35
Study 18197453 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic resection
Number of subjects: 201
Study 18197453 — intervention group
Group type: COMPARATOR
Intervention: Open resection
Number of subjects: 201
Study 16423519 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's Wort (PM235) - lower dose (0.12% hypericine)
Number of subjects: 150
Study 16423519 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's Wort (PM235) - higher dose (0.18% hypericine)
Number of subjects: 150